| Literature DB >> 22289889 |
Fabien Guilloton1, Gersende Caron, Cédric Ménard, Céline Pangault, Patricia Amé-Thomas, Joëlle Dulong, John De Vos, Delphine Rossille, Catherine Henry, Thierry Lamy, Olivier Fouquet, Thierry Fest, Karin Tarte.
Abstract
Accumulating evidence indicates that infiltrating stromal cells contribute directly and indirectly to tumor growth in a wide range of cancers. In follicular lymphoma (FL), malignant B cells are found admixed with heterogeneous lymphoid-like stromal cells within invaded lymph nodes and BM. In addition, mesenchymal stromal cells (MSCs) support in vitro FL B-cell survival, in particular after their engagement toward lymphoid differentiation. We show here that BM-MSCs obtained from patients with FL (FL-MSCs) display a specific gene expression profile compared with MSCs obtained from healthy age-matched donors (HD-MSCs). This FL-MSC signature is significantly enriched for genes associated with a lymphoid-like commitment. Interestingly, CCL2 could be detected at a high level within the FL-cell niche, is up-regulated in HD-MSCs by coculture with malignant B cells, and is overexpressed by FL-MSCs, in agreement with their capacity to recruit monocytes more efficiently than HD-MSCs. Moreover, FL-MSCs and macrophages cooperate to sustain malignant B-cell growth, whereas FL-MSCs drive monocyte differentiation toward a proangiogenic and lipopolysaccharide-unresponsive phenotype close to that of tumor-associated macrophages. Altogether, these results highlight the complex role of FL stromal cells that promote direct tumor B-cell growth and orchestrate FL-cell niche, thus emerging as a potential therapeutic target in this disease.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22289889 DOI: 10.1182/blood-2011-08-370908
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113